To observate when necrosis in metastases of renal cell cancer is occurring.
ID
Source
Brief title
Condition
- Reproductive neoplasms female benign
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Observational. Measurement of Kep, Ktrans, R2*, b-coefficent (perfusion,
hypoxia, blood volume and necrosis)
Secondary outcome
No
Background summary
Sutent is a new angiogenesis inhibitor. It is used in the treatment of renal
cell cancer. Very frequently necrosis inside the metastases is seen after start
of treatment with Sutent. After how many days this effect in the tumor is
starting, is not known. We would like to investigate this, because this has
consequences for future research.
Study objective
To observate when necrosis in metastases of renal cell cancer is occurring.
Study design
In 5 patients with renal cell carcinoma, which will be treated with Sutent, 3
MRIs will be made: before start, after 3 days and after 10 days.
Study burden and risks
The patient will undergo 3 times a MRI. Small risks are an allergic reaction on
the contrast fluid or a hematoma due to the punction in the vein.
P.O. Box 9101
6500 HB Nijmegen
Nederland
P.O. Box 9101
6500 HB Nijmegen
Nederland
Listed location countries
Age
Inclusion criteria
- patients with metastatic renal cell cancer for whom treatment with Sutent is planned
- measurable primary tumor or metastases (minimal diameter 2 cm) at other sites than the lungs
- Karnofsky score equal or larger than 70%
- age equal or higher than 18 year.
- written informed consent
Exclusion criteria
- contra-indications for MRI
- contra-indications for treatment with Sutentâ
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL15264.091.06 |